Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.

ABSTRACT:

Background

Ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death in women world-wide. Three-quarters of women present when the disease has spread throughout the abdomen (stage III or IV) and treatment consists of a combination of debulking surgery and platinum-based chemotherapy. Although initial responses to chemotherapy are good, most women will relapse and require further chemotherapy and will eventually develop resistance to chemotherapy.PARP (poly (ADP-ribose) polymerase) inhibitors, are a novel type of medication that works by preventing cancer cells from repairing their DNA once they have been damaged by other chemotherapy agents. It is not clear how PARP inhibitors compare to conventional chemotherapy regimens for the treatment of ovar

SUBMITTER: Wiggans AJ 

PROVIDER: S-EPMC6457589 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature